Clinical Trial Readiness for Children 0-5 years with Congenital Muscular Dystrophy Secondary to LAMA2 Mutations

Medicine & Life Sciences

1. Muscular Dystrophies 100%
2. Clinical Trials 60%
3. Child 56%
4. Mutation 41%
5. Health Care Outcome Assessment 25%
6. Minimal Clinically Important Difference 14%
7. Biomarkers 12%
8. Motor Disorders 12%
9. Hamstring Muscles 12%
10. Laminin 10%
11. Pandemics 10%
12. Creatine Kinase 10%
13. Drug Development 9%
14. Genes 7%
15. Up-Regulation 7%
16. Pediatrics 6%
17. Apoptosis 5%